|
US2020390902A1
|
|
Antibody-Drug Conjugates Targeted at Human Aspartyl-(Asparaginyl)-B-Hydroxylase (HAAH)
|
|
US2019049455A1
|
|
HAAH and MMP-9 are Complementary Cancer Biomarkers and Predictors of Metastasis when Combined
|
|
US2017072034A1
|
|
Therapeutic cancer vaccine targeted to haah (aspartyl-[asparaginyl]-beta-hydroxylase)
|
|
CN107690334A
|
|
Radiophotography and radiotherapy using the antibody for HAAH to cancer
|
|
WO2016040941A1
|
|
Recovery of aspartyl (asparaginyl) beta hydroxylase (haah) from an exosomal fraction of human sera from cancer patients
|
|
US2014271691A1
|
|
Therapeutic cancer vaccine targeted to HAAH (aspartyl-[asparaginyl]-β-hydroxylase)
|
|
WO2009139925A1
|
|
Methods for the treatment of brain edema
|
|
WO2009059309A2
|
|
Furin-cleavable peptide linkers for drug-ligand conjugates
|
|
AU2007333791A1
|
|
Methods of neuroprotection by cyclin-dependent kinase inhibition
|
|
WO2007087646A2
|
|
Methods of diagnosing, predicting therapeutic efficacy and screening for new therapeutic agents for leukemia
|
|
AU2006318558A1
|
|
Methods of treating ischemic related conditions
|
|
AU2004236690A1
|
|
Methods of treating ischemic related conditions
|
|
CN1816336A
|
|
The chemical compound of treatment ischemic related conditions
|
|
AU2002345843A1
|
|
Compositions and methods for preventing protein aggregation in neurodegenerative diseases
|
|
AU2002303802B2
|
|
Diagnosis and treatment of malignant neoplasms
|
|
EP1392305A2
|
|
Methods for treating neurodegenerative diseases including alzheimer's
|
|
EP1330267A1
|
|
Olfactory neuron cultures and method of making and using the same
|
|
US7521479B2
|
|
Methods of treating prion disease in mammals
|
